
Atossa Genetics (ATOS) Stock Forecast & Price Target
Atossa Genetics (ATOS) Analyst Ratings
Bulls say
Atossa Therapeutics Inc. is highlighted as a promising investment due to its focus on developing proprietary treatments for significant medical needs in oncology and COVID-19, specifically through its lead drug, Endoxifen, as well as therapies AT-H201 and AT-301. The company's current valuation is considered attractive, with recent adjustments indicating a bullish outlook, signifying an increase in estimated value based on net present value (NPV) analyses. Moreover, the anticipated achievement of key clinical milestones and positive data is expected to serve as strong catalysts for the stock's performance moving forward.
Bears say
Atossa Therapeutics reported a net loss of $8.7 million for the period, reflecting a consistent earnings per share of $(0.07), which aligns with prior results but falls short of consensus estimates, highlighting a trend of persistent losses. The company faces significant risks, including balance sheet and liquidity challenges, potential failures of its drug candidates in clinical trials, and difficulties in gaining regulatory approval and commercialization. These factors, combined with competitive pressures and fluctuating investor sentiment in the biotech sector, contribute to a negative outlook for Atossa Therapeutics's stock.
This aggregate rating is based on analysts' research of Atossa Genetics and is not a guaranteed prediction by Public.com or investment advice.
Atossa Genetics (ATOS) Analyst Forecast & Price Prediction
Start investing in Atossa Genetics (ATOS)
Order type
Buy in
Order amount
Est. shares
0 shares